by RAND Corporation Credit: Unsplash/CC0 Public Domain The cost of buying the opioid antidote naloxone is out of reach for many uninsured Americans, a hurdle that may keep the treatment from saving more people who overdose on opioids, according to a new RAND Corporation study. While laws making it easier to prescribe and obtain naloxone...
